Skip to main content
OpenTrials
Completed

NCT Number: NCT05926791

Photoprotective Effects of a SPF50+ Sunscreen on Skin Genotoxicity Induced by Repeated Chronic Outdoor Sun Exposure

Between 2 and 3 million non-melanoma skin cancers and 132,000 melanoma skin cancers occur globally each year. Sun protection continues to be a major public health issue and has always been a priority research area for Pierre Fabre laboratories. The involvement of ultraviolet radiation of the solar spectrum in skin carcinogenesis is well known, through its ability to damage the DNA of skin cells and the induction of oxidative processes.

The aim of this exploratory study is to perform the quantification of:

* DNA photoproducts excised from the genome by the biological repair systems in urine samples * cellular DNA damage in the epidermis following chronic exposure to natural sunlight.

This study will allow us to better understand and quantify the benefit of sunscreens on photoinduced cellular damage and their elimination in urine.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Skin Research Center

Toulouse, France

About this study

This trial is a monocentric, exploratory, randomized, controlled, open-label, parallel-group study conducted in healthy adult subjects.

The target population consists of subjects who are accustomed to using few products or using low protection index during sun exposure.

The study area is the whole body for sun exposure. The target areas are the face and forearms for the samplings and measurements.

In this design, in order not to impose any strong constraint to the subjects in terms of sun exposure, the duration of the exposure period is left free and can vary between 5 and 21 days. Within this window, subjects can freely determine their sun exposure episodes (choice of time slot, number and duration). However, subjects have to expose themselves for at least 3 hours /day, for 5 days in the week prior to visit 2 (which will be scheduled no more than 3 days after their last sun exposure).

The study includes 3 visits:

  • Visit 1: Inclusion (D1)
  • Visit 2: Intermediate visit (D7 to D39)
  • Visit 3: Wound healing evaluation and end of study (V2 + 15 days +/- 2 days)

The period of outdoor sun exposure varies between 5 and 21 days depending on the duration planned by the subjects themselves. This is also the duration of application of the investigational product for the subjects in group 1.

Visit 1 can be performed up to 15 days before the beginning of the sun exposure period and visit 2 up to 3 days after the last sun exposure.

The duration of participation for a subject varies between 20 and 56 days (from inclusion to the end of the study).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female adults aged between 18 and 55 years included
  • Subject with a habit of using little or no sunscreen products with low protection index (SPF < 25) during sun exposure.
  • Subject's commitment to have a self-reported sun exposure of at least 3 hours per day for the 5 days of their last week of vacation
  • Subjects agreeing not to expose themselves to UVs (natural or artificial) before the planned outdoor sun exposure period

Exclusion criteria

  • - Criteria related to the population:
  • Smoker of more than 10 cigarettes per day containing nicotine, paper and/or electronic cigarette equivalent
  • Subject having received on study areas artificial UV exposure or excessive, prolonged, and unprotected exposure to natural sunlight within the 4 weeks before the inclusion visit or planning one during the study
  • Subject having performed excessive and prolonged physical activity (e.g. trail, long distance running, race…) within 7 days before the inclusion visit
  • - Criteria related to the diseases / skin condition:
  • Subject with a known history of photosensitivity (toxic, allergic)
  • Subject with a known personal or family history of skin cancer
  • Subject having hereditary or acquired disorders of hemostasis.
  • - Criteria related to the treatments and/or products:
  • Physical treatment (radiotherapy, phototherapy, chemical peeling, laser, ...) on the study area within 4 weeks before the inclusion visit or planned during the study.
  • Systemic or topical treatment applied on the study area (e.g. anti-allergic, anti-inflammatory treatment) within two weeks before the inclusion visit, ongoing or planned during the study and likely to interfere with the study according to the investigator's assessment
  • Use of anti-aging products (containing retinoids and / or α-hydroxy acids) on the target areas (face and/or forearms) in the 2 weeks before the inclusion visit.
  • Systemic or topical treatment with photosensitizing or phototoxic potential (NSAIDs, antihistamines, psychotropic drugs, antidepressants, anti-migraine drugs, cyclines, quinolone, antibiotics, beta-blockers, etc.), taken or applied to the study area within the previous weeks, ongoing or planned during the study, and likely to interfere with the study according to the investigator's assessment
  • Subject taking creatine dietary supplements and/or practicing prolonged fasting

Treatment and study plan

Cosmetic product

Other

The educated group receives the cosmetic product SPF50+ according to the randomization list established at V1 and returns the products at V2

Primary outcomes

  1. Change in photoinduced DNA damage products in urine samples before and after outdoor sun exposure

    Time frame: Change from baseline (day 1) to visit 2 (occuring between day 7 to 39 depending on the duration of sun exposure)

    Quantitative analysis of photoinduced DNA damage products by high performance liquid chromatography-coupled to tandem Mass Spectrometry (HPLC/MS-MS)

  2. Number of CPD (Cyclobutane Pyrimidine Dimer) lesions in epidermal samples collected from the forearm following the outdoor sun exposure period

    Time frame: Day 7 to 39 (depending on the duration of sun exposure)

    Number of CPD (Cyclobutane Pyrimidine Dimer) lesions in epidermal samples by high performance liquid chromatography-coupled to tandem Mass Spectrometry (HPLC/MS-MS)

  3. Change in colorimetric parameters before and after outdoor sun exposure

    Time frame: Change from baseline (day 1) to visit 2 (between day 7 to 39 depending on the duration of sun exposure)

    Colorimetric parameters assessed by chromametry on the face and forearm

  4. Change in pigmentation parameters before and after outdoor sun exposure

    Time frame: Change from baseline (day 1) to visit 2 (between day 7 to 39 depending on the duration of sun exposure)

    Pigmentation parameters assessed by Multispectral analysis on the face and forearms

  5. Change in cellular damages before and after outdoor sun exposure

    Time frame: Change from baseline (day 1) to visit 2 (between day 7 to 39 depending on the duration of sun exposure) up to visit 3 ( between day 20 to 56)

    Cellular damage assessed by Mass spectrometry lipid analysis in D-Squame samples collected on the face and forearm before and after outdoor sun exposure

Sponsors and collaborators

Lead sponsor

Pierre Fabre Dermo Cosmetique

Industry

Registry information

Official study title

Evaluation of the Photoprotective Effects of a SPF50+ Sunscreen on Photo-induced Cell Damage in Epidermal and Urine Samples, Following a Repeated Chronic Outdoor Sun Exposure in Healthy Adults

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Jul 3, 2023
Registry last updated
Jul 3, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.